Press Releases
-
2022-09-27Kancera reports good progress of recruitment in ongoing phase IIa study of KAND567 in myocardial infarction and the decision to allow for recruitment of additional patients
-
2022-09-22Kancera reports convincing preclinical results and decision to initiate clinical development of KAND567 in ovarian cancer
-
2022-08-22Interim report second quarter, January 1 – June 30, 2022, Kancera ab (publ.), org.nr. 556806-8851